Dyadic International, Inc. (DYAI): Price and Financial Metrics


Dyadic International, Inc. (DYAI): $5.17

-0.07 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DYAI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

DYAI Stock Summary

  • DYAI's went public 1.98 years ago, making it older than just 3.58% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Dyadic International Inc is higher than it is for about merely 0.35% of US stocks.
  • DYAI's price/sales ratio is 88.93; that's higher than the P/S ratio of 95.95% of US stocks.
  • Stocks that are quantitatively similar to DYAI, based on their financial statements, market capitalization, and price volatility, are GNMK, CLXT, MRAM, ESTC, and PSTG.
  • Visit DYAI's SEC page to see the company's official filings. To visit the company's web site, go to www.dyadic.com.

DYAI Stock Price Chart Interactive Chart >

Price chart for DYAI

DYAI Price/Volume Stats

Current price $5.17 52-week high $10.98
Prev. close $5.24 52-week low $4.56
Day low $5.10 Volume 77,600
Day high $5.34 Avg. volume 578,354
50-day MA $5.55 Dividend yield N/A
200-day MA $6.84 Market Cap 142.45M

Dyadic International, Inc. (DYAI) Company Bio


Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.


DYAI Latest News Stream


Event/Time News Detail
Loading, please wait...

DYAI Latest Social Stream


Loading social stream, please wait...

View Full DYAI Social Stream

Latest DYAI News From Around the Web

Below are the latest news stories about Dyadic International Inc that investors may wish to consider to help them evaluate DYAI as an investment opportunity.

DYAI: Headed to the Clinic

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT 2020 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) released 2020 operational and financial results on March 30, 2021 and concurrently filed its Form 10-K with the SEC. A Phase I trial is planned in 2H:21 that will evaluate the safety of a C1-produced vaccine in human subjects. Following the

Yahoo | April 8, 2021

Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript

Dyadic International Inc (DYAI) Q4 2020 Earnings Conference Call March 30, 2021 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Ronen Tchelet - Vice President of Research and Business Development Conference Call Participants Jason Kolbert - Dawson James John...

SA Transcripts on Seeking Alpha | March 31, 2021

Dyadic International EPS beats by $0.01, misses on revenue

Dyadic International (DYAI): FY GAAP EPS of -$0.34 beats by $0.01.Revenue of $1.6M (-4.8% Y/Y) misses by $0.3M.Shares -0.38%.Press Release...

Seeking Alpha | March 30, 2021

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial

Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further pre-clinical and clinical developmentTo validate C1 produced proteins are safe in humans and accelerate C1 adoption To serve as proof of concept for next generation variant based COVID-19 vaccine candidates Expanded Korea and South East Asia vaccine development partnership with Medytox (086900)(KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boosters In parallel with DYAI-100, Dyadic is developing additional proprietary owned and third party COVID-19 variant vaccine candidates Developing a number of other infectious disease vaccines and antibodies internally and in conjun...

Yahoo | March 29, 2021

CEO’s Presenting on the Emerging Growth Conference on March 31. Register now.

Niche Companies in Tech, Pharma, Cannabis, Finance and more in AttendanceMIAMI, March 29, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 4th Emerging Growth Conference. EmergingGrowth.com is proud to present and welcome you to the 4th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. The schedule for March 31st from 9:30 AM until 4:00 PM is as follows: (All times are Eastern Tim...

Yahoo | March 29, 2021

Read More 'DYAI' Stories Here

DYAI Price Returns

1-mo 4.44%
3-mo -3.00%
6-mo -28.79%
1-year N/A
3-year 237.91%
5-year 202.34%
YTD -3.90%
2020 3.86%
2019 174.07%
2018 35.97%
2017 -16.27%
2016 -8.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9322 seconds.